A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

Table 2 Utility values derived from the utility valuation survey [37]

Health State	N	Mean utility value	SD	95% CI
Medication with atomoxetine; responder without side effects	83	0.959	0.077	0.942 – 0.976
Medication with atomoxetine; responder with side effects	83	0.937	0.096	0.916 – 0.958
Medication with atomoxetine; non-responder without side effects	83	0.902	0.133	0.873 – 0.931
Medication with atomoxetine; responder with side effects	83	0.886	0.148	0.854 – 0.918
Medication with IR-MPH; responder without side effects	83	0.913	0.128	0.885 – 0.941
Medication with IR-MPH; responder with side effects	83	0.904	0.137	0.875 – 0.933
Medication with IR-MPH; non-responder without side effects	83	0.889	0.154	0.856 – 0.922
Medication with IR-MPH; responder with side effects	83	0.875	0.164	0.840 – 0.910
Medication with XR-MPH; responder without side effects	83	0.930	0.107	0.907 – 0.953
Medication with XR-MPH; responder with side effects	83	0.912	0.124	0.885 – 0.939
Medication with XR-MPH; non-responder without side effects	83	0.898	0.130	0.870 – 0.926
Medication with XR-MPH; responder with side effects	83	0.884	0.143	0.853 – 0.915
No medication; responder	23	0.880	0.133	0.826 – 0.934
No medication; non-responder	23	0.880	0.133	0.826 – 0.934

Abbreviations: IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; SD = standard deviation

ISSN: 1471-244X